Authorities in Belgium are investigating the death of a 46-year-old woman perhaps linked to a counterfeit or illegally obtained version of the weight-loss drug Ozempic, highlighting a growing international concern over the risks of unregulated pharmaceuticals.the examination, unfolding in Pelt and Lommel, comes amidst a surge in demand for drugs like Ozempic – initially intended for type 2 diabetes but increasingly used off-label for weight loss [[1]].These incidents serve as a stark warning against sourcing prescription medications outside of established medical channels, where the authenticity and dosage cannot be verified.
Belgian authorities are investigating the death of a 46-year-old woman who may have died from an overdose of a weight-loss drug, according to multiple reports. The case highlights the increasing risks associated with obtaining prescription medications through illicit channels.
The woman, a resident of Pelt, Belgium, reportedly died after taking an illegal version of Ozempic, a medication typically prescribed for type 2 diabetes but increasingly used off-label for weight loss. According to early reports, she acquired the drug outside of official pharmaceutical supply chains.
Prosecutors have launched an investigation into the circumstances surrounding her death, focusing on how she obtained the medication. Authorities in Lommel are also investigating a similar case involving a 46-year-old woman who may have died after using a illegally purchased weight-loss drug.
“He didn’t realize he was offering something that wasn’t allowed,” HLN reported, citing sources close to the investigation regarding the Pelt case. The investigation is attempting to determine the source of the counterfeit or illegally obtained medication.
The incidents have prompted warnings about the dangers of purchasing prescription drugs from unregulated sources. Officials are concerned about the potential for counterfeit medications or incorrect dosages, which can have life-threatening consequences. The development underscores the growing demand for weight-loss drugs and the risks associated with seeking them through unofficial channels.
